摩熵化学
数据开放平台 数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(benzylsulfanyl)-5-[(naphthalen-1-yloxy)methyl]-4-phenyl-4H-1,2,4-triazole

中文名称
——
中文别名
——
英文名称
3-(benzylsulfanyl)-5-[(naphthalen-1-yloxy)methyl]-4-phenyl-4H-1,2,4-triazole
英文别名
3-benzylsulfanyl-5-(naphthalen-1-yloxymethyl)-4-phenyl-1,2,4-triazole
3-(benzylsulfanyl)-5-[(naphthalen-1-yloxy)methyl]-4-phenyl-4H-1,2,4-triazole化学式
CAS
——
化学式
C26H21N3OS
mdl
——
分子量
423.5
InChiKey
LEDFCRCFWZPAOY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.2
  • 重原子数:
    31
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    65.2
  • 氢给体数:
    0
  • 氢受体数:
    4

文献信息

  • Certain triazole-based compounds, compositions, and uses thereof
    申请人:Hodge Nicholas Carl
    公开号:US20050288347A1
    公开(公告)日:2005-12-29
    Thiotriazole-based chemical entities exhibiting ATP-utilizing enzyme inhibitory activity, methods of using such chemical entities, and compositions comprising such chemical entities, are described.
    描述了具有 ATP 利用酶抑制活性的代三唑类化学实体、使用此类化学实体的方法以及包含此类化学实体的组合物。
  • SMALL MOLECULE ACTIVATORS OF NRF2 PATHWAY
    申请人:THE GENERAL HOSPITAL CORPORATION
    公开号:US20160101098A1
    公开(公告)日:2016-04-14
    This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Specifically, the compounds provided herein can act as high affinity reversible bindings for the NRF2 inhibitor, KEAP1. In some cases, NRF2/KEAP1/ARE pathway activation compounds are capable of repressing expression of inflammatory markers and/or reducing levels of TNFa to provide neuroprotective anti-inflammatory effects in the CNS. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer.
  • US9737525B2
    申请人:——
    公开号:US9737525B2
    公开(公告)日:2017-08-22
  • [EN] SMALL MOLECULE ACTIVATORS OF NRF2 PATHWAY<br/>[FR] ACTIVATEURS DE PETITES MOLÉCULES DE LA VOIE NRF2
    申请人:GEN HOSPITAL CORP
    公开号:WO2014197818A2
    公开(公告)日:2014-12-11
    This disclosure relates to compounds that act as activators of the NRF2/KEAP1/ARE pathway. Such compounds are useful in the treatment of a variety of diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease, inflammation, and cancer.
查看更多